IR-Med Inc. (IRME)
| Market Cap | 234.04K -84.8% |
| Revenue (ttm) | n/a |
| Net Income | -2.35M |
| EPS | -0.03 |
| Shares Out | 111.45M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,100 |
| Open | 0.0021 |
| Previous Close | 0.0011 |
| Day's Range | 0.0021 - 0.0021 |
| 52-Week Range | 0.0010 - 0.0527 |
| Beta | 0.72 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 21, 2026 |
About IR-Med
IR-Med Inc., a medical device company, engages in the development of non-invasive devices for various medical indications. The company’s development products pipeline consists of PressureSafe, a handheld skin-agnostic optical monitoring device that supports early detection of pressure injuries to the skin and underlying tissue primarily caused by prolonged pressure associated with bed confinement; DiaSafe, a handheld optical monitoring device, which supports early detection of diabetic foot ulcers in lower limb skin and underlying tissue caused... [Read more]
Financial Performance
Financial StatementsNews
IR-MED Ltd. Announces Launch of First-in-Human Clinical Trial of Its DiaSafe(TM) Device for Diabetic Foot Ulcer (DFU) Assessment
DiaSafe™ technology for non-invasive DFU risk assessment and early intervention* The DFU treatment market is estimated to be approximately$10 billion globally 1 Rosh Pina, Israel--(Newsfile Corp. - No...
IR-MED's Key Clinical and Media Milestones
PressureSafe(TM) clinical results presented to global nursing leaders; the Company engages with U.S. investment community and national media in parallel visibility push Rosh Pina, Israel--(Newsfile Co...
IR-MED Investor Update Letter - Sept-2025
Rosh Pina, Israel--(Newsfile Corp. - September 16, 2025) - IR-MED Inc. (OTCQB: IRME) ("IR-MED" or the "Company"), a developer of non-invasive artificial intelligence (AI)-powered spectrographic techno...
IR-MED Reports Positive Interim Results from U.S. Clinical Study of PressureSafe(TM) for Pressure Injury Assessment Across Diverse Skin Tones
PressureSafe™, IR-MED's lead product, demonstrated 94% sensitivity in assessing tissue at risk for pressure injuries prior to visible skin breakdown Technology addresses longstanding disparities in sk...
IR-MED Awarded $500,000 Grant from the Israel Innovation Authority to Advance AI-Powered DiaSafe(TM) Device for Diabetic Foot Ulcer Assessment
DiaSafe™, IR-MED's second product, is being developed to provide safe, real-time optical readings of biomarkers for assessment of diabetic foot ulcers The most common cause of amputation, diabetic foo...
IR-MED CEO Issues Letter to Shareholders: Expanding Our Platform and Presenting New Clinical Data from Israel and the U.S.
Rosh Pina, Israel, March 18, 2025 (GLOBE NEWSWIRE) -- IR-MED Inc. (“IR-MED” or the “Company”) (OTCQB: IRME), a developer of noninvasive, AI-driven spectrographic analysis technology addressing signifi...
Methodist Healthcare Adopts IR-MED's PressureSafe™ Device for Usability Study: Decision Support Device Aims to Reduce Substantial Healthcare Burden of Pressure Injuries
Rosh Pina, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc. , (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis tec...
IR-MED Appoints Ran Ziskind, Tech Entrepreneur, Growth Manager, and Inventor as Chief Executive Officer
Rosh Pina, Israel, Aug. 28, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis techn...
IR-MED Wins Prestigious Netty Award for Best Up-and-Coming Health Tech Company
Rosh Pina, Israel, Aug. 21, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis techn...
IR-MED Receives $500,000 Grant from the Israel Innovation Authority to Develop its Platform Technology for the Early Detection of Diabetic Foot Ulcers
Rosh Pina, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- I R-MED Inc. , (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis tec...
IR-MED's PressureSafe™ Reduced Pressure Injuries by 50% During a Usability Study with Clalit, Israel's Largest HMO
Poster presentation available here: LINK
IR-MED's PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries
Rosh Pina, Israel, April 05, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc. , (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis tec...
IR-MED Reports 92% Efficacy for PressureSafe™ in Early, Non-Invasive, Skin Color Agnostic Detection of Pressure Injuries
Rosh Pina, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc. , (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis tech...
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16
Rosh Pina, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc. , (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis tech...
IR-MED Awarded Most Innovative Non-Invasive Diagnostics Technology Developer 2023 by Corporate Vision Magazine
Rosh Pina, Israel, Dec. 21, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis techn...
IR-MED Granted Patent in Israel for its AI-Driven Platform Technology: Non-Invasive Analysis of Subcutaneous Tissue
The Granted patent covers IR-MED's PressureSafe ™ decision support device for the early detection of pressure injuries addressing a healthcare burden that amounts to $26.8 billion in the U.S. annually...
IR-MED Appoints Healthcare Executive and Entrepreneur Tzur Di-Cori as Chief Executive Officer
Mr. Di-Cori's vast healthcare experience includes President of LifeWatch Technologies, a developer of technologies that help physicians detect symptoms before they become major health problems
IR-MED to Conduct Usability Study with Methodist Healthcare of San Antonio for its PressureSafe Device Which is Slated for U.S. Launch in H1 2024
Rosh Pina, Israel, Sept. 26, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis tech...
IR-MED Appoints Richard Serbin, Esq. to its Advisory Board
Rosh Pina, Israel, Sept. 13, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), a developer of a noninvasive AI-driven spectrographic analysis technology platform to addre...
IR-MED Chairman & Interim CEO Issues Letter to Shareholders
Rosh Pina, Israel, Aug. 21, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive AI-driven infrared spectrographic analysis technology platform to...
IR-MED's AI-Powered Infra-Red Spectrographic Decision Support System PressureSafe Device Demonstrates High Efficacy in Detecting Pressure Injuries with 96% Accuracy: Potential to Set a New Standard of Care
Rosh Pina, Israel, July 17, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive AI-driven Infra-Red spectrographic analysis technology platform t...
IR-Med Appoints Dr. Lynn Eschenbacher to its Advisory Board as Company Advances Toward Launch of its PressureSafe Wound Care Device
Rosh Pina, Israel, June 07, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive AI-driven spectrographic analysis technology platform to address ...
IR-Med's PressureSafe Noninvasive Wound Care Device to be Demonstrated at Northwell Health's 10th Annual Shining the Light on Wound Care Symposium
Rosh Pina, Israel, May 19, 2023 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive AI-driven spectrographic analysis technology platform to address s...
IR-Med to present at National Pressure Injury Advisory Panel 2023
The company's PressureSafe device is being designed to reduce healthcare disparity in pressure injury detection and treatment
IR-MED SIGNS AGREEMENT TO EXPAND ITS PRESSURESAFE DEVICE USABILITY STUDY
The study will expand to Rabin Medical Center (RMC), in parallel to Beit-Rivka, turning the study to a double c enter usability study.